Control Bionics Ltd.

As of June 30, 2024, Control Bionics Ltd. carries a market capitalization of 10.36M, placing it among publicly traded companies globally. Its enterprise value stands at 10.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Control Bionics Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2024, Control Bionics Ltd. has 202.75M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 1.62, and the price-to-book ratio stands at 1.65.

These figures are as of June 30, 2024. The EV/Sales ratio of 2.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.34M versus a market cap of 10.36M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Control Bionics Ltd. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.34, indicating elevated leverage, while an interest coverage ratio of -110.99 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Control Bionics Ltd. posted a negative return on equity (ROE) of -88.16, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -66.73, reflecting losses generated across the asset base. Inventory turnover of 2.41 indicates how many times Control Bionics Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Control Bionics Ltd.'s stock has gained approximately 54.29% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.06.

Over the twelve months ended June 30, 2024, Control Bionics Ltd. generated 5.13M in revenue and converted that into -5.91M in net income, yielding earnings per share of -0.04. EBITDA reached -6.25M, while operating income came in at -7.09M.

As of June 30, 2024, Control Bionics Ltd. holds 980,760.00 in cash and equivalents against 961,738.00 in total debt, resulting in a net debt position of -463,624.00. Total book value stands at 6.27M, with working capital of 1.36M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Control Bionics Ltd. posted a gross margin of 71.64, reflecting its pricing power and cost economics. The operating margin of -138.29 and net profit margin of -115.35 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -52.38, meaning Control Bionics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Control Bionics Ltd.'s most recent stock split took place on September 4, 2025 with a 115:117 split ratio.

As of June 30, 2024, Control Bionics Ltd. has an Altman Z-Score of -9.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.